I didn’t think I could get addicted to weed. I was wrong – and I’m not alone – The Guardian
#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to recognize that cannabis use disorder is a genuine clinical condition affecting a significant population, contrary to widespread public misconception that cannabis is non-addictive. Understanding THC’s neurobiological mechanism of action on dopaminergic reward pathways enables clinicians to provide accurate patient education, identify dependence symptoms, and offer appropriate treatment interventions rather than dismissing cannabis-related concerns. This knowledge gap between public perception and clinical reality directly impacts screening practices, diagnosis rates, and patient outcomes in primary care and mental health settings.
Cannabis use disorder (CUD) represents a significant but underrecognized clinical problem, with approximately 9% of cannabis users and up to 17% of adolescent users developing dependence despite widespread perception that cannabis is non-addictive. THC’s activation of the brain’s reward system through dopamine release creates genuine neurobiological addiction potential comparable to other substances, particularly with modern high-potency products containing 15-30% THC or greater. Clinical presentations of CUD include tolerance requiring escalating doses, withdrawal symptoms such as irritability and sleep disturbance, and continued use despite negative consequences, yet many patients and even some providers minimize these risks due to cannabis’s legal status in many jurisdictions. Clinicians should screen for problematic cannabis use patterns during substance use assessments and counsel patients, particularly adolescents with developing brains, about realistic addiction risk rather than perpetuating the myth of harmlessness. The practical takeaway is that clinicians must update their understanding of cannabis dependence potential and incorporate evidence-based screening and patient education into routine care to address this prevalent but often minimized form of substance use disorder.
“Cannabis use disorder is “real” and used in diagnostic circles based on the existing diagnostic criteria. And it is increasingly common, in my practice and beyond, particularly among patients using high-potency products without understanding the neurobiological basis for dependence. I’ve found that honest screening and psychoeducation about THC’s effects on the reward system is often more helpful than dismissal or shame. And we, as a medical culture, must reevaluate the diagnostic criteria and decide if we think the diagnosis (and management) warrant a fresh look
? While cannabis is often perceived as non-addictive compared to other substances, emerging evidence and patient narratives highlight that cannabis use disorder is a genuine clinical entity affecting a meaningful proportion of regular users, particularly those consuming high-potency products or using daily. The neurobiological mechanisms underlying cannabis addiction—involving dopamine dysregulation and reward pathway sensitization—are well-established, though individual vulnerability varies based on genetics, age of initiation, and concurrent mental health conditions. Clinicians should recognize that many patients may not spontaneously report cannabis dependence due to lingering cultural perceptions of harmlessness, normalization in some communities, and the absence of obvious physical withdrawal symptoms in some users, potentially leading to underdiagnosis. Given the rising potency of available cannabis products and increasing daily use patterns, it is practical and important to routinely screen for cannabis use disorder during substance use assessments, particularly in patients presenting with mood or anxiety symptoms,
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
